share_log

HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $12

HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $12

HC Wainwright & Co.維持對Rani Therapeutics Hldgs的買入,將目標股價下調至12美元
Moomoo 24/7 ·  03/25 06:06

HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $16 to $12.

HC Wainwright & Co. 分析師米切爾·卡普爾維持Rani Therapeutics Hldgs(納斯達克股票代碼:RANI)的買入並將目標股價從16美元下調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論